Path pps was barely affected by FDA approval for migraine skin patch, followed by upgrade to Strong Buy. Looks like it will be affected more by quarter's earnings, needs cash to launch its product.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.